Sean Vasaitis

  • T. Sean Vasaitis, Ph.D.

    Assistant Professor, Pharmaceutical Sciences

    Dr. Vasaitis completed his doctoral work in Molecular Pharmacology and Experimental Therapeutics at the University of Maryland School of Medicine in 2007.  He holds a masters degree in Exercise and Health Science from Miami University, Ohio and a bachelors degree in Biology from the University of Maryland, Eastern Shore.

    Prior to his appointment at the UMES School of pharmacy, Dr. Vasaitis was a research fellow with Dr. Angela Brodie and Dr. Vincent Njar at the University of Maryland, Baltimore (UMB).  At UMB he was involved in the development of novel inhibitors of androgen action for the treatment of prostate cancer.  He also is involved in clinical research in the Geriatric Research, Education and Clinical Center at the Baltimore Veterans Affairs Medical Center investigating the mechanisms by which exercise, vitamin D and complementary therapeutics affect metabolic function.    

    Dr. Vasaitis’ research goals follow the overarching concept of integrating Western approaches to medicine and pharmacological therapy with evidence-based complementary medicine to further a holistic approach to disease treatment.  In addition to his research in novel drug development and metabolic function, he has taught taijiquan (tai chi) to patients with stroke, cancer, multiple sclerosis, cardiovascular disease and diabetes as part of studies with Johns Hopkins Prohealth, the University of Maryland School of Medicine, and within his own business practice. 

    Selected publications

    Wang, Q., T. S. Udayakumar, T. S. Vasaitis, A. M. Brodie and J. D. Fondell (2004). "Mechanistic relationship between androgen receptor polyglutamine tract truncation and androgen-dependent transcriptional hyperactivity in prostate cancer cells." J Biol Chem 279(17): 17319-28.

    Handratta, V. D.*, T. S. Vasaitis*, V. C. Njar, L. K. Gediya, R. Kataria, P. Chopra, D. Newman, Jr., R. Farquhar, Z. Guo, Y. Qiu and A. M. Brodie (2005). "Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model." J Med Chem 48(8): 2972-84.

    Purushottamachar, P., A. Khandelwal, T.S. Vasaitis, R. Bruno, L. K. Gediya, and V. C. Njar (2008). “Potent anti-prostate cancer agents derived from a novel androgen receptor down-regulating agent.” Bioorg Med Chem 16(7):3519-29.

    Moreira, V. M., T. S. Vasaitis, V. C. Njar and J. A. Salvador (2008). "Synthesis of novel C17 steroidal carbamates Studies on CYP17 action, androgen receptor binding and function, and prostate cancer cell growth." Steroids 73(12):1217-27.

    Vasaitis, T., A. Belosay, A. Schayowitz, A. Khandelwal, P. Chopra, L. Gediya, Z. Guo, H. Fang, V. C. Njar and A. M. Brodie (2008). “Androgen Receptor Inactivation Contributes to Antitumor Efficacy of CYP17 Inhibitor VN/124-1 in Prostate Cancer.” Mol Cancer Ther. 7(8):2348-57.

    Brodie, A., V. Njar, L.F. Macedo, T.S. Vasaitis, G. Sabris (2009). "The Coffey Lecture: Steroidogenic enzyme inhibitors and hormone dependent cancer," Urol Oncol. 27(1):53-63.

    Vasaitis, T.S., V.C.O. Njar (2010). "Novel,potent anti-androgens of therapeutic potential: recent advances and promising developments." Fut. Med. Chem. 2(4):667-680.

    Vasaitis, T.S., R. Bruno, V. Njar (2010). "CYP17 Inhibitors for prostate cancer therapy." J. Steroid Biochem Mol Biol 2010. Nov. 17. [Epub ahead of print]

    Bruno RD, Vasaitis TS, Gediya LK, Purushottamachar P, Godbole AM, Ates-Alagoz Z, Brodie AM, Njar VC (2011). Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): Head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model. Steroids. Nov;76(12):1268-79.